A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Vaidya, Ashok
- Marketed Ayurvedic Antidiabetic formulations: Labeling, Drug Information and Branding
Authors
1 Symbiosis International University, Pune, IN
2 Kasturba Health Society's Medical Research Centre, ICMR Advanced Centre for Reverse Pharmacology in Traditional Medicine Medical Research Center-KHS, 17, Khandubhai Desai Road, Vile Parle (West), Mumbai 400 056, IN
3 Ayurvidye Trust, Bangalore, IN
4 Kasturba Health Society's Medical Research Centre, Mumbai, IN
5 The Interdisciplinary School of Health Sciences, Pune, IN
Source
The Indian Practitioner, Vol 66, No 10 (2013), Pagination: 631-639Abstract
Diabetic patients, in India are known to take one or more Marketed Ayurvedic Antidiabetic Formulations (MAAF) alone or with the conventional drug/s as over the counter or through self medication. The labeling information is crucial for patient information and safety besides fulfilling the regulatory needs. for drugs from any system of medicine. The present study was aimed at to study MAAF for patient information, regulatory compliance and patient safety.The labels of 180 MAAF were analysed as to the details of brand names, dosage forms, ingredients, composition, dosage schedule and precautions. Package inserts of additional fifty three MAAFs were reviewed for the compliance.
The ingredients used in the products varied widely, as to the plants' identity, parts and extracts used and their concentrations. The dosage of the ingredients ranged from a few mgs to 2-3 gms, depending on raw herbs or extracts used. The current labels, studied for the composition details, did not clearly indicate the quantity of each ingredient to the original raw herb quantum. There was a wide variation in the way composition was printed on the label. The study shows a need for improvement in compliance to labeling regulations. There was no information about the suitability of these drug's administration in pregnancy and/or lactation.,or specific dose and drug formulation for paediatric and geriatric groups.
Brand names studied have chiefly reflected antidiabetic/Madhumehaghna activity. However, some of the brand names like Sugar Knocker, Sugar balance etc convey exaggerated claims. Drug regulators may continue to license MAAF with brand names but sanction those that could be misleading. Ayurvedic manufacturers need to consider and register their trade names under Trade Mark Registration Act to avoid duplicity and misuse of same names, across the state of India.
Keywords
Ayurvedic Antidiabetic Medicine, Ayurvedic Pharmacoepidemiology, Drug Regulation, Brand Names, Labeling and Package Inserts, MAAF.
- Epidemic Dropsy
Authors
1 Medical Research Centre, ICMR-Advanced Centre of Reverse Pharmacology, Kasturba Health Society, Mumbai, Maharashtra, IN
Source
The Indian Practitioner, Vol 69, No 5 (2016), Pagination: 21-22Abstract
No Abstract.References
- Anon. News worth knowing: A new disease. Vaidya Kalpataru, 1907;12:238-239.
- Lyon IB. Textbook of Medical Jurisprudence for India, 1st edn. 1889; p 214.
- Manson-Bahr. Plant poisons. In: Manson’s Tropical diseases, 16th edn. London:Bailliere, Tindalland Cassell Ltd, 1982; pp 571-2.
- Deodhar NS. Epidemic dropsy in Poona 1959. Maharashtra Med J. 1970; 17:131-8.
- Shah MJ, Manghani KK, Sheth UK, Mehta JM, Karandikar PV. Epidemic dropsy: epidemiological, clinical and therapeutic observations in 67 cases. Indian J Med Res. 1969; 57:1878-91.
- Mukherjee SP, Lal RB, Mathur KBL. Investigation into the epidemiology of epidemic dropsyXII. Isolation of active substances from toxic oils. Indian J Med Res. 1941;29:361-5.
- Lal RB, Dasgupta AC. Investigation into epidemiology of epidemic dropsy X: a note on an outbreak of epidemic dropsy associated with the use of mustard oil pressed from adulterated seed. Indian J Med Res. 1941;29: 157-63.
- Chopra RN, Pasricha CL, Goyal RK, Lal S, Sen AK. The experimental production of syndrome of epidemic dropsy in man. Indian Med Gaz. 1939; 74:193-8.
- Sarkar SN. Isolation from argemone oil of dihydrosanguinarine and sanguinarine: toxicity of sanguinarine. Nature. 1948; 162:265
- Tandon S, Das M, Khanna SK. EVect of sanguinarine on the transport of essential nutrients in an everted gut sac model: role of Na+ , K+ -ATPase. Natural Toxins. 1993;1:235-40.
- Nandi R, and Maiti M. Binding of sanguinarine to deoxyribonucleic acids of diVering base composition. Biochem Pharmacol.1985;34:321-4.
- Maiti M, Nandi R, Chaudhuri K. Interaction of sanguinarine with natural and synthetic deoxyribonucleic acids. Indian J Biochem Biophys.1984;21:158-65.
- Hakim SA. Argemone oil, sanguinarine, dropsy, glaucoma and cancer. Indian Pract.1967;20(1):129-41.
- Hakim SA. Sanguinarine-a carcinogenic contaminant in Indian edible oils. Indian J Cancer. 1968;5(2):183-97.
- Vaidya AB, Rajagopalan TG, Kale AG, Levine RJ. Inhibition of human pregnancy plasma diamine oxidase with alkaloids of Argemone mexicana-berberine and sanguinarine. J Postgrad Med.1980;26:28-33.
- Willcox M L, Graz B, Falquet J et al. Argemone mexicana Decoction for the Treatment of Uncomplicated Falciparum Malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2007;101(12): 1190-1198.
- Scope of Ayurceuticals in Integrative Antenatal Care: Challenges and Opportunities
Authors
1 Kasturba Health Society-Medical Research Center, 17, KD Road, Vile Parle (W), Mumbai 400056, IN